Work

Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.501

Authors: Maura N. Dickler, William Thomas Barry, Constance T. Cirrincione, Matthew James Ellis, Mary Ellen Moynahan, Federico Innocenti, Arti Hurria, Hope S. Rugo, Diana Lake, Olwen Mary Hahn, Bryan P. Schneider, Debu Tripathy, Eric P. Winer, Clifford A. Hudis

Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Duke University, Washington University in St. Louis, University of North Carolina at Chapel Hill, City Of Hope National Medical Center, City of Hope, University of California, San Francisco, University of Chicago, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2600754550

Cites:

Cited by: 16

Related to: 10